ClinicalTrials.gg
RecruitingNCT07135271BeSpokeUpdated Jul 29, 2026

BeSpoke Decision Support for Patients With Newly Diagnosed Localised Prostate Cancer

An interventional study of Bespoke Decision Support tool and Standard of Care (SOC) decision support material in Localised Prostate Cancer, sponsored by University College, London. Recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by University College, London · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
346
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Prostatic Neoplasms by University College, London — 9 open to participants now, 17 under way, 3 of them phase 3. Prostatic Neoplasms · University College, London.

Planned enrollment
14th of 20
346 · median 454
Started
2026
with 4 others
No phase
10 of 32
5 open now
Primary completion
2027-11
later than 8 of 16 live
Registered
29th of 32
by date

Among the 32 studies in Prostatic Neoplasms by University College, London, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 with no phase, reaches primary completion later than 8 of the 16 other live ones, and was the 29th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 32 studies in Prostatic Neoplasms by University College, London are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Prostatic Neoplasms by University College, London, or all of them as a file.
02

Study summary

The goal of this randomised clinical trial is to assess whether personalised treatment counselling can improve the decision-making experience in patients with a new diagnosis of localised prostate cancer. The main question it aims to answer is:

  • Does the Bespoke Decision Support tool reduce decisional conflict in those choosing between treatment options for localised prostate cancer?

Researchers will compare the addition of the Bespoke Decision Support tool to standard treatment counselling versus standard counselling alone.

Patient participants will:

  • Receive standard counselling with or without access to the Bespoke Decision Support tool (based on arm of randomisation), prior to making a treatment decision.
  • Answer to questionnaires regarding urinary, sexual and bowel function and decision-making outcomes before and after making a treatment decision and at 3, 6, and 12 months after initiating treatment.
  • Take part in a qualitative interview to discuss their decision-making experience

Health Care Professional participants will:

  • Take part in a qualitative interview to discuss their experience in providing decision support in the trial using the Bespoke Decision Support tool.
Read the detailed description

Recruited patient participants will be randomised into two arms:

  • Standard of Care (SOC) arm: SOC counselling
  • Intervention arm: SOC counselling plus access to BeSpoke Decision Support

The standard of care (SOC) arm includes the nationally-approved Prostate Cancer UK booklet "Prostate Cancer - A guide if you have recently been diagnosed" and patient appointments to discuss different treatments with clinicians, as per local practice that offer them. Further educational material may be provided as per local practice at each site.

The intervention arm will offer additional BeSpoke Decision Support providing:

  • Consistent and up-to-date information about suitable treatment approaches.
  • Risk-stratified predictions of treatment outcomes based on baseline cancer and patient characteristics.
  • Value clarification about which attributes of treatment are most important to the individual.

All participants will complete questionnaires on demographic data, functional status and measures of decision-making experiences at several time points: enrolment (prior to treatment discussion consultation); after treatment decision has taken place; at 3, 6, and 12 months after treatment commences.

The investigators will interview health care professionals and a sample of patient participants to assess the effect of the BeSpoke Decision Support and the challenges in implementation across the NHS.

03

Conditions studied

  • Localised Prostate Cancer

Browse trials for

Keywords

  • Localised Prostate Cancer
  • Patient Decision Aid
  • Shared Decision Making
  • Randomised Clinical Trial
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Patient-Participants:

  1. Newly diagnosed localised prostate cancer
  2. Clinically suitable for at least two of the following treatment options:

    1. active surveillance
    2. focal therapy
    3. radical prostatectomy
    4. external beam radiotherapy
  3. Willing and able to provide

Exclusion Criteria for Patient Participants:

  1. Unsuitable for active treatment due to very low risk prostate cancer or significant health issues.
  2. Suspicion of prostate cancer based on clinical or imaging evidence including:

    1. Imaging identified suspicious lesion on bone scan, CT, whole-body MRI or PSMA-PET/CT;
    2. PSA ≥50 ng/mL.
  3. Not able to provide informed consent.
  4. Insufficient English proficiency for adequate use of BeSpoke Decision Support. (Patients with support from a family member, friend or partner, to overcome lack of English proficiency will be included.)
  5. Enrolled in other localised prostate cancer studies where treatment is assigned rather than chosen by participants, e.g. PART Trial (Partial prostate Ablation vs Radical prostaTectomy)

Inclusion criteria for Health Care Professionals:

  1. Have seen BeSpoke Decision Support and spoken to patients in the intervention arm.
  2. Willing and able to provide written or electronic informed consent

Exclusion criteria for Health Care Professionals

1. No experience of BeSpoke Decision Support.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
346 participants (estimated)

Study arms

  • Placebo comparator
    Standard of Care (SOC)

    Standard of Care Counselling information

    Other: Standard of Care (SOC) decision support material

  • Experimental
    BeSpoke Decision Support

    Standard of care counselling plus access to BeSpoke Decision Support tool

    Other: Bespoke Decision Support tool · Other: Standard of Care (SOC) decision support material

Interventions

  • OtherBespoke Decision Support tool

    A newly-developed online patient decision aid offering comparative information of prostate cancer treatments (active surveillance, focal therapy, radical prostatectomy and external beam radiotherapy), personalised estimates of oncological and functional outcomes for each treatment and a value-clarification exercise.

  • OtherStandard of Care (SOC) decision support material

    Standard of care information to inform the prostate cancer treatment decision. This includes the nationally approved Prostate Cancer UK information booklet "Prostate Cancer - A guide if you have just been diagnosed" in all sites. Further educational material may be provided as part of standard of care depending on local practice at each site.

06

What researchers measure

Primary outcomes

  1. Decisional Conflict Scale (DCS)

    Mean difference in DCS between control (SOC) arm and intervention (Bespoke Decision Support) groups. Scores range from 0 \[no decisional conflict\] to 100 \[extremely high decisional conflict\].

    Time frame: After treatment decision is confirmed, assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment.

Secondary outcomes

  1. Preparation for Decision Making (PrepDM) Scale

    Mean difference in PrepDM Scale between control and intervention group. Scores range from 0 to 100 \[higher scores indicate higher perceived level of preparation for decision making\].

    Time frame: After treatment decision is confirmed, assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment.

  2. Decision Self Efficacy (DSE) Scale

    Mean difference in the DSE score between the control and the intervention groups. Scores range from 0 \[not at all confident\] to 100 \[very confident\].

    Time frame: After treatment decision is confirmed, assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment.

  3. Satisfaction With Decision (SWD) Scale

    Mean difference in the SWD score between the control and the intervention groups. Scores range from 1 to 5 (5=higher satisfaction).

    Time frame: Measured at multiple time points: after treatment decision is confirmed (assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment); and at 3, 6 and 12 months from the treatment date.

  4. Decision Regret Scale (DRS)

    Mean difference in the DRS score between the control and the intervention groups. Scores range from 0 \[no regret\] to 100 \[high regret\].

    Time frame: Measured at multiple time points: after treatment decision is confirmed (assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment); and at 3, 6 and 12 months from the treatment date.

  5. Satisfaction with Cancer Information Profile (SCIP) Scale

    Mean difference in the SCIP score between the control and the intervention groups at time-point 1 and time-point 4. Scores for the sub-scale "Satisfaction with the amount and content of information" range from 1 to 14 (14=higher satisfaction). Scores for the sub-scale "Satisfaction with the form and timing of information" range from 7 (lower satisfaction) to 35 (higher satisfaction).

    Time frame: Measured after treatment decision is confirmed (assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment) and at 12 months after treatment initiation.

  6. Control Preference Scale (CPS)

    Frequencies and proportion of the CPS categories in both the intervention and the control group.

    Time frame: Measured at enrolment and after treatment decision is confirmed (assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment).

  7. Hospital Anxiety and Depression Scale (HADS)

    Frequencies and proportion of the HADS categories in both the intervention and the control group. Scores range from 0 to 21: 0-7 = Normal; 8-10 = Borderline abnormal (borderline case); 11-21 = Abnormal (case).

    Time frame: Measured before giving intervention, and after 3, 6 and 12 months from treatment initiation.

  8. Decisional Conflict Scale (DCS) Subscales

    Means or medians of the intervention and the control groups for the different DCS sub-scores: * Informed sub-score (Scores range from 0 \[feels extremely informed\] to 100 \[feels extremely uninformed\]); * Values Clarity sub-score(Scores range from 0 \[feels extremely clear about personal values for benefits \& risk/side effects\] to 100 \[feels extremely unclear about personal values\]); * Support sub-score (Scores range from 0 \[ feels extremely supported in decision making\] to 100 \[feels extremely unsupported in decision making\]); * Uncertainty sub-score (Scores range from 0 \[feels extremely certain about best choice\] to 100 \[feels extremely uncertain about best choice\]); * Effective Decision sub-score (Scores range from 0 \[good decision\] to 100 \[bad decision\]).

    Time frame: After treatment decision is confirmed, assessed as patient-reported outcome measure via questionnaire delivered on average after 4 weeks from enrolment.

  9. Qualitative Assessment with Patients

    Qualitative interview evaluating patient experience in treatment decision making and feedback on decision support material

    Time frame: Between treatment decision being recorded and end of study (12 months after treatment initiation)

  10. Qualitative assessment with Health Care Professionals (HCP)

    Qualitative interviews with HCP (urologists, clinical oncologists, clinical nurse specialists, GPs) involved in the treatment decision making pathway of patients with prostate cancer, to inquire regarding the decision support material provided as standard of care and in the intervention arm.

    Time frame: Through study completion, an average of 1 year

Other outcomes

  1. Number of treatment counselling consultations

    Mean or median difference in number of treatment counselling consultations taking place between enrolment and treatment decision between the control and intervention group.

    Time frame: From date of randomisation until the date of first documented recording of treatment decision, assessed up to 12 months.

  2. Treatment choice

    Proportion of different treatments chosen (active surveillance, focal therapy, radical prostatectomy and radiotherapy) between the intervention and the control groups.

    Time frame: From date of randomisation until the date of first documented recording of treatment decision, assessed up to 12 months.

  3. Time to treatment decision

    Time passed between enrolment and recording of treatment decision between the control and intervention group.

    Time frame: From date of randomisation until the date of first documented recording of treatment decision, assessed up to 12 months.

07

Study locations

1 of 1 sites recruiting
  • University College London Hospitals NHS Foundation Trust
    London, NW1 2BU, United Kingdom
    Recruiting
    • Davide Maffei · Contactdavide.maffei@nhs.net · +44 20 3108 2718
    • Caroline M Moore · Principal investigator
    • Davide Maffei · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Any request to share IPD from other researchers will be evaluated by the Trial Steering Committee on an ad hoc basis.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Nov 2027, 16 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 16 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 22, 2025
StartActual
Jul 22, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07135271
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Jul 22, 2026
Primary completion
Nov 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 29, 2026

Study contacts

Davide Maffei, MD
Contact
d.maffei@ucl.ac.uk
+44 (0)20 7679 2000
NCITA Clinical Trial Unit
Contact
ncita.bespoke@ucl.ac.uk
Caroline M Moore, MD
principal investigator · University College, London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion